touchNEUROLOGY touchNEUROLOGY
Neuromuscular Diseases
Read Time: 2 mins

Letter from the Editor-in-Chief

Copy Link
Published Online: Dec 20th 2016 European Neurological Review, 2016;11(2):78 DOI: https://doi.org/10.17925/ENR.2016.11.02.78
Authors: Cris S Constantinescu
Quick Links:
Article
Article Information
Article:

I am delighted to take on the role of Editor-in-Chief for European Neurological Review and would like to introduce myself. I studied medicine in Boston University, US, and specialised in neurology in Philadelphia. I then moved to Europe and worked on multiple sclerosis (MS) in Switzerland for two years. For the past 17 years, I have been working in Nottingham, UK, and in 2004 I became professor and head of clinical neurology at the University of Nottingham, Queen’s Medical Centre. My main research interest is in the immunological mechanisms underlying MS, particularly dysregulation of cytokines. An early aim of my research was modulating the immune system to treat MS, an approach that has now become widely used. I also have an interest in imaging modalities in MS, particularly the detection of white matter and grey matter damage for the purposes of discovering subtle disease, and using imaging modalities as outcome measures in clinical trials.

European Neurological Review is a unique source for presenting meetings and satellite symposia, and it also produces very high quality review articles. As Editor-in-Chief, I would like to diversify the range of topics to include diagnostic methods as well as clinical aspects and new research on neurological diseases. I am confident that European Neurological Review will gain inclusion on PubMed, which would be advantageous for the journal. The journal has a global reach, which is reflected in its editorial board. I look forward to working with everyone involved in developing the journal. To all prospective authors, I would like to encourage you to submit both reviews and original research manuscripts. We offer advice to all authors and for those whose articles are accepted, and we will ensure that they reach their target audience. To readers, I hope you find the journal relevant, interesting and attractive to read.

Further Resources

Share this Article
Related Content In Neuromuscular Diseases
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72